Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q05996
UPID:
ZP2_HUMAN
Alternative names:
Zona pellucida glycoprotein 2; Zona pellucida protein A
Alternative UPACC:
Q05996; B2R7J2; Q4VAN9; Q4VAP0; Q4VAP1
Background:
Zona pellucida sperm-binding protein 2, also known as Zona pellucida glycoprotein 2 or Zona pellucida protein A, plays a crucial role in fertilization. It is a component of the zona pellucida, an extracellular matrix that surrounds oocytes. This protein mediates critical processes such as sperm binding, induction of the acrosome reaction, and prevention of post-fertilization polyspermy, primarily acting as a secondary sperm receptor.
Therapeutic significance:
The protein is linked to Oocyte/zygote/embryo maturation arrest 6, an autosomal recessive infertility disorder characterized by oocyte fertilization failure. Understanding the role of Zona pellucida sperm-binding protein 2 could open doors to potential therapeutic strategies for treating infertility issues related to sperm-binding abnormalities.